Walter E. Aulitzky

Stuttgart, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma.

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma.

Journal: Journal of visualized experiments : JoVE

Published: September 29, 2025

BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains.

BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains.

Journal: EMBO reports

Published: September 07, 2023

ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.

ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.

Journal: Cell death & disease

Published: July 18, 2023

Author Correction: Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis.

Author Correction: Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis.

Journal: Nature communications

Published: January 10, 2023

Perfusion Air Culture of Precision-Cut Tumor Slices: An Ex Vivo System to Evaluate Individual Drug Response under Controlled Culture Conditions.

Perfusion Air Culture of Precision-Cut Tumor Slices: An Ex Vivo System to Evaluate Individual Drug Response under Controlled Culture Conditions.

Journal: Cells

Published: December 08, 2022

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 06, 2022

Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis.

Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis.

Journal: Nature communications

Published: January 12, 2022

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA.

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA.

Journal: Cell death discovery

Published: October 08, 2021

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.

Journal: Frontiers in immunology

Published: May 06, 2021

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.

Journal: Haematologica

Published: March 06, 2021

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.

Journal: Cancer discovery

Published: January 29, 2021

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

Journal: The Lancet. Haematology

Published: December 28, 2020

Showing 1-12 of 40

Last Updated: 09/26/2026